@entity1311 and XXXX co-loaded polymeric nanoparticles for the effective combination therapy against human @entity421 .

@entity5 @entity8813 @entity1311 @entity4045 @entity2879 @entity7050 @entity421
BACKGROUND: The combination of chemotherapeutic drugs with different pharmacological action has emerged as a promising therapeutic strategy in the treatment of @entity5 . Present study examines the antitumor potential of @entity1311 ( @entity4045 ) and @entity2879 ( @entity8813 )-loaded @entity7050 nanoparticles for the treatment of @entity421 . RESULTS: The resulting drug-loaded @entity7050 NP exhibited a nanosize dimension with uniform spherical morphology. The NP exhibited a sustained release profile for both @entity4045 and @entity8813 throughout the study period without any sign of initial burst release. The combinational drug-loaded @entity7050 NP enhanced the cytotoxic effect in MG63 and Saos-2 @entity421 cell lines, in comparison to either native drug alone or in cocktail combinations. Additionally, NPs showed an appreciable uptake in MG63 cells in a time-based manner. Co-delivery of anticancer drugs resulted in enhanced cell cycle arrest and cell apoptosis. The results clearly showed that combinational drugs remarkably improved the therapeutic index of chemotherapeutic drugs. The greater inhibitory effect of nanoparticle combination would be of great advantage during systemic @entity5 therapy. CONCLUSION: Taken together, our study demonstrated that @entity4045 - @entity8813 / @entity7050 NP based combination therapy holds significant potential towards the treatment of @entity421 .
